Spectral Medical Inc is inPhase III, seeking FDA approval for its theranostics product for the treatment of severe sepsis and septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay, Spectral's EUPHRATES trial is a theranostics trial in the area of sepsis.
135 2 The West Mall
Toronto, ON M9C 1C2